Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Ribociclib

    Virtual Booth

    Contact Supplier

    Ribociclib

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Ribociclib Succinate

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ribociclib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,176Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 8Kisqali

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Kisqali

    Ribociclib

    arrow
    Biotech Showcase
    Not Confirmed

    Brand Name : Kisqali

    Switzerland
    arrow
    Biotech Showcase
    Not Confirmed

    Novartis

    Ribociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 687

    2019 Revenue in Millions : 480

    Growth (%) : 43

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Kisqali

    Ribociclib

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Kisqali

    Switzerland
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Novartis

    Ribociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 937

    2020 Revenue in Millions : 687

    Growth (%) : 36

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Kisqali

    Ribociclib

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Kisqali

    Switzerland
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Novartis

    Ribociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 1,231

    2021 Revenue in Millions : 937

    Growth (%) : 31

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Kisqali

    Ribociclib

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Kisqali

    Switzerland
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Novartis

    Ribociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 2,080

    2022 Revenue in Millions : 1,231

    Growth (%) : 69

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Kisqali

    Ribociclib

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Kisqali

    Switzerland
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Novartis

    Ribociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 3,033

    2023 Revenue in Millions : 2,080

    Growth (%) : 46

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Kisqali

    Ribociclib

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Kisqali

    Switzerland
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Novartis

    Ribociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 76

    2016 Revenue in Millions : 0

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Kisqali

    Ribociclib

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Kisqali

    Switzerland
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Novartis

    Ribociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 235

    2017 Revenue in Millions : 76

    Growth (%) : 209%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Kisqali

    Ribociclib

    arrow
    BIO Partnering at JPM
    Not Confirmed

    Brand Name : Kisqali

    Switzerland
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Novartis

    Ribociclib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 480

    2018 Revenue in Millions : 235

    Growth (%) : 104

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.